NPM1 and acute myeloid leukemia: Thus, both these latter subgroups are currently considered favorable according to the 2017 ELN risk stratification, contrary to NPM1-mutated AML associated with FLT3-ITD with high allelic ratio, which is characterized by a higher relapse rate and poorer overall survival (OS) [10].